Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

The latest update is out from Xenon ( ($XENE) ). Xenon Pharmaceuticals has granted equity inducement awards to ten new non-officer employees, issui...

Xenon Pharmaceuticals Issues Inducement Stock Options to New Hires

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolus (EOLS – Research Report) and Xenon (XENE – ...

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Xenon (XENE)

Xenon ( ($XENE) ) has provided an announcement. Xenon Pharmaceuticals Inc. announced that President and CEO Ian Mortimer will present a company upd...

Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference

Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Xenon on January 2 and set a price target of $55.00. The company’s shares clos...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$41.82	+0.89%	390.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$41.82	+0.9%	390.21K
3
4
5
6

XENE

XENE

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel